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background:  This study sought to assess vascular healing at 9 months after implantation of everolimus-and biolimus-eluting stents 
(EES, BES) and everolimus-eluting bioresorbable vascular scaffold (BVS) by optical coherence tomography (OCT). This is a formal 
substudy of the Comparison of Everolimus-and Biolimus-Eluting Coronary Stents with Everolimus-Eluting Bioresorbable Vascular Scaffolds 
Randomized Controlled Trial (EVERBIO II), which was a single center, randomized controlled superiority trial.
methods:  A total of 74 patients enrolled in the EVERBIO II Trial were investigated by OCT at 9-month follow-up angiography. OCT images 
were acquired using the pullback and non-occlusive flushing technique. Results were compared between patients treated by EES&BES vs. 
patients treated by BVS.
results:  OCT analysis was performed in 26 EES-treated lesions in 23 patients (7,625 struts), in 26 BES-treated lesions in 23 patients 
(6,140 struts) and in 33 BVS-treated lesions in 28 patients (10,891 struts). A total of 3,039 (22%) struts were uncovered in the EES&BES 
group compared with 366 (3%) in the BVS group (p<0.001). There were 583 (4%) malapposed struts in EES&BES-treated compared to 
213 (2%) struts in BVS-treated patients (p<0.001). The percentage of uncovered struts per stent or scaffold treated lesions was lower for 
BVS compared to EES&BES (EES&BES: 22±14% vs. BVS: 4±8%, p<0.001), but there was no significant difference in the percentage of 
malapposed struts per lesion (EES&BES: 4±9% vs. BVS: 2±3%, p=0.6). Mean neointima thickness per lesion was 65±38µm for EES&BES 
and 100±45µm for BVS, respectively (p < 0.001). Peri-strut low intensity area was higher in BVS-treated patients.
Conclusion:  BVS stents demonstrate higher lesion capping with lessened incomplete apposition but higher peri-strut low intensity area at 
9-month follow-up when compared with EES and BES. It is not known whether this improved capping is a correlate of vascular healing. The 
clinical significance of these findings needs to be assessed.
